Delcath Systems Inc

DCTH remains in a Stage 2 advancing phase with long- and medium-term uptrends intact. However, price is extended and marked as extremely overbought, consolidating above the rising EMAs without a clear upside trigger. Execution is deferred until a pullback into the 9/21 EMA support zone resolves, offering a lower-risk entry aligned with the advancing structure.

• ↑Q1 2026 revenue $25M (+26% YoY), driven by Hepsado sales of $23.3M
• ↑Gross margin at 85% underscores high treatment profitability
• ↓Q1 2026 net loss of $1.1M highlights ongoing profitability shortfall